Russia has approved the use of R-Pharm's drug Coronavir in the treatment of outpatients with mild to moderate COVID-19 disease.
>
According to Arabnet, the antiviral drug will be available in pharmacies across the country at the earliest next week.
the approval to use coronavir as a prescription treatment comes after another Russian drug, avivavir, was approved in May.
are based on favipiravir, which was developed in Japan and is widely used there as the basis for anti-viral treatments.
On the other hand, the CEO of Moderna Corporation suggested that sufficient data are available from trials of the emerging corona virus vaccine; To see the extent of his success in the experiments by next November, according to Reuters.
The CEO of the company, Stephane Bansel, said that our company plans to obtain an emergency use license for at-risk groups, if the vaccine proves to be at least 70 percent effective. . Moderna, the candidate vaccine, is nearing the finish line as it seeks to register 30,000 people at a late stage of trials. As of Wednesday evening, the company had registered 25,296 participants in recent vaccine trials, according to Al-Khaleej newspaper.
and it is possible that the company will announce its success early, if it is able to demonstrate that the people who got the vaccine did better in the trials, compared to those who did not on him. The vaccine must prove to be at least 50 percent more effective than the alternative treatment used in trials, to be considered for approval.
And our company announced, at the end of August, that positive results were reached among the elderly in trials of the vaccine it is developing. The company found that the immune response, for people aged 56 years and over, was the same as response rates in younger age groups, which is an encouraging sign for this group most at risk of contracting Covid-19 disease caused by the virus, according to the description of the Wall Street Journal.
(Amazon fun knowledge)
